The gold standard remains randomized, double-blind, placebo-controlled experimentation, ideally with active placebos when side effects may unblind participants. Cross-over designs are attractive for within-person sensitivity, but they require careful handling of carryover effects and washout periods. Pre-registration, power analysis, and robust statistical plans are essential because cognitive effect sizes are often small.

No single behavioral task can capture cognition comprehensively. Researchers therefore combine task batteries, subjective reports, ecological momentary assessment, physiological signals, and sometimes biomarkers such as EEG, pupillometry, heart-rate variability, or neuroimaging measures. Yet biomarkers are not automatically surrogates: they must be validated against meaningful cognitive outcomes.

Modern enhancement research increasingly uses hierarchical modeling, Bayesian inference, mediation analysis, and machine learning to characterize heterogeneous response patterns. These tools can identify responder subgroups, dose-response relations, and latent constructs more effectively than single endpoint tests. However, complexity can also increase the risk of overfitting and false discovery.